Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine- nab-paclitaxel in advanced pancreatic cancer
{{output}}
Background: Novel biomarkers, such as plasma microRNAs (miRs), are needed to help guide clinical decision-making for the type of chemotherapy to use in patients with advanced pancreatic ductal adenocarcinoma (PDAC). This study as... ...
